Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

BACKGROUND: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug therapy. This study evaluated the effects of MetS factors (abdominal ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, Jeffrey B., Ballantyne, Christie M., Hsueh, Willa A., Lin, Jianxin, Shah, Arvind K., Lowe, Robert S., Tershakovec, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559874/
https://www.ncbi.nlm.nih.gov/pubmed/26336957
http://dx.doi.org/10.1186/s12944-015-0075-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559874/
https://www.ncbi.nlm.nih.gov/pubmed/26336957
http://dx.doi.org/10.1186/s12944-015-0075-5

Ejemplares similares